Zura Bio (ZURA) to Release Earnings on Wednesday

Zura Bio (NASDAQ:ZURA) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 9:30 AM ET.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.31). On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Stock Performance

Shares of ZURA stock opened at $5.93 on Monday. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $7.44. The firm has a market capitalization of $385.59 million, a price-to-earnings ratio of -5.59 and a beta of 0.18. The stock’s 50-day simple moving average is $6.23 and its 200-day simple moving average is $4.69.

Analysts Set New Price Targets

A number of analysts recently commented on ZURA shares. Oppenheimer lowered their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Friday, March 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Wedbush initiated coverage on shares of Zura Bio in a report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price target for the company. Finally, Chardan Capital lifted their price objective on shares of Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Insider Buying and Selling at Zura Bio

In other news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of Zura Bio stock in a transaction dated Thursday, February 26th. The stock was purchased at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the purchase, the insider directly owned 6,552,725 shares in the company, valued at $40,954,531.25. This trade represents a 43.93% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 14.23% of the company’s stock.

Hedge Funds Weigh In On Zura Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Scientech Research LLC purchased a new position in Zura Bio during the 3rd quarter worth approximately $45,000. AQR Capital Management LLC purchased a new stake in shares of Zura Bio in the 1st quarter valued at $72,000. Bank of America Corp DE boosted its holdings in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Zura Bio in the third quarter worth $109,000. Finally, Jane Street Group LLC acquired a new stake in shares of Zura Bio in the second quarter worth $113,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.